Alnylam Pharmaceuticals, Inc.
ALNY
$292.03
$7.192.52%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 577.22M | 352.98M | 82.79M | -279.86M | -230.47M |
| Total Depreciation and Amortization | 54.81M | 55.66M | 56.32M | 56.50M | 57.56M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 606.35M | 560.23M | 606.67M | 442.07M | 450.48M |
| Change in Net Operating Assets | -525.47M | -446.78M | -481.92M | -236.24M | -324.67M |
| Cash from Operations | 712.90M | 522.08M | 263.87M | -17.54M | -47.11M |
| Capital Expenditure | -71.56M | -58.70M | -44.50M | -36.55M | -30.27M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 368.58M | 495.03M | 465.08M | -74.22M | 94.82M |
| Cash from Investing | 297.02M | 436.33M | 420.59M | -110.77M | 64.55M |
| Total Debt Issued | 645.69M | 645.69M | 646.37M | -- | -- |
| Total Debt Repaid | -1.19B | -1.19B | -1.14B | -- | -- |
| Issuance of Common Stock | 213.82M | 250.03M | 244.61M | 274.90M | 326.46M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -434.00K | -6.27M | -68.11M | -41.31M | -15.13M |
| Cash from Financing | -333.56M | -303.19M | -317.51M | 233.59M | 311.33M |
| Foreign Exchange rate Adjustments | 13.81M | 34.94M | 23.37M | 39.39M | 8.76M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 690.17M | 690.16M | 390.30M | 144.67M | 337.53M |